NS-863 Low Dose + NS-863 High Dose + NS-863 Placebo
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Jul 1, 2026 → Nov 1, 2028
NCT ID
NCT07441200About NS-863 Low Dose + NS-863 High Dose + NS-863 Placebo
NS-863 Low Dose + NS-863 High Dose + NS-863 Placebo is a phase 2 stage product being developed by Nippon Shinyaku for Pulmonary Arterial Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07441200. Target conditions include Pulmonary Arterial Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07441200 | Phase 2 | Recruiting |
Competing Products
20 competing products in Pulmonary Arterial Hypertension